Welcome to Advanced Vaccine Therapeutics
AVTH: A New York Based Biotechnology Company
Click here to download Investor Presentation
AV Therapeutics Begins Trading on the OTCQB Under the Symbol “AVTH”
SEC Filing Details
Why develop immunotherapeutic
vaccines for cancers?
- All cancers are immunogenic, that is our body can detect and kill cancers.
- Our proprietary technology, using non-toxic peptides which mimic the cancer proteins, re-educates the immune system so that the cancer cells are detected and killed.
- The technology provides a constant source of novel reagents that can be uniquely used for cancer prevention and therapy.
AVT is primarily engaged in the business of developing Cancer Therapeutics and Immunotherapeutic Vaccines that can be used together with prevalent treatment modalities such as chemotherapy and radiation to treat active disease and to prevent metastases and recurrence. Scientists at AVT have identified and patented a chemotherapeutic drug called Capridine that has shown in preclinical models to have specific activity against prostate and colon cancer. This drug is expected to be the frontline AVT product specifically in prostate cancer where no chemotherapy exists at present. The Company’s immunotherapeutics is based on the ability of certain proprietary reagents to re-educate or reprogram a failed immune system that can target previously unidentified micro-metastases. The Company intends to clinically develop both of these approaches independently specifically for prostate cancer.
It is the goal of the Founders of AVT that the therapeutic agents used will first eliminate the cancer and then the immunotherapeutic peptides.
Scientists involved with AVT have identified and patented a chemotherapeutic drug called Capridine that has shown in preclinical models to have specific activity against prostate and colon cancer.